Catalyst Biosciences Announces Appointment of Grant Blouse, Ph.D., as Vice President of Translational Research
Catalyst Biosciences, Inc.
Jul. 10, 2018
SOUTH SAN FRANCISCO, Calif., July 10, 2018 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (Nasdaq:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced the appointment of Grant Blouse, Ph.D., as vice president of translational research.
“We are delighted that Dr. Grant Blouse will be joining Catalyst as vice president of translational research,” said Nassim Usman, chief executive officer of Catalyst. “Dr. Blouse brings over 20 years of experience in hematology research and development, including most recently supporting coagulation R&D programs at Novo Nordisk for six years. He will be supporting the development of our hemophilia programs and our research pipeline. We are confident in his ability to immediately contribute to our Factor IX CB 2679d/ISU304 and Factor VIIa marzeptacog alfa clinical programs.”
Dr. Blouse was most recently principle scientist and project manager at Novo Nordisk A/S, Haemophilia Enzymology, where he led early and late stage hemophilia projects and drove the strategic evaluation of new therapeutic areas in the rare disease space. Prior to Novo Nordisk, Dr. Blouse was a senior scientist at Catalyst Biosciences where he helped to build Catalyst’s next-generation hemophilia franchise, including helping to identify Catalyst’s Factor VIIa candidate marzeptacog alfa (activated) and co-inventing its Factor IX candidate CB 2679d/ISU304. Dr. Blouse has held research and investigator positions at Aarhus University’s Department of Molecular Biology, Henry Ford Health System’s Division of Biochemical Research and Wayne State University School of Medicine’s Department of Pharmacology. He has authored more than 50 peer reviewed papers and abstracts and delivered more than a dozen invited talks in the biochemistry and hematology spaces. Dr. Blouse earned his B.A. in anthropology from the University of Delaware, his M.Sc. in biochemistry from Clemson University and his Ph.D. in pharmacology from Wayne State University School of Medicine.
About CatalystCatalyst is a clinical-stage biopharmaceutical company developing novel medicines to address hematology indications. Catalyst is focused on the field of hemostasis, including the subcutaneous prophylaxis of hemophilia and facilitating surgery in individuals with hemophilia. For more information, please visit www.catalystbiosciences.com.
Forward-Looking StatementsThis press release contains forward-looking statements that involve substantial risks and uncertainties. Forward-looking statements include statements about the potential for Catalyst’s product candidates, including its subcutaneously administered product candidates, to address hemophilia indications, and its plans to advance these product candidates. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that the Company makes, including, but not limited to, the risk that trials and studies may be delayed and may not have satisfactory outcomes, that human trials will not replicate the results from animal studies, that potential adverse effects may arise from the testing or use of the Company’s products, including the generation of antibodies, the risk that costs required to develop or manufacture the Company’s products will be higher than anticipated, competition and other factors that affect our ability to establish collaborations on commercially reasonable terms and other risks described in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2017 along with other filings with the Securities and Exchange Commission. The Company does not assume any obligation to update any forward-looking statements, except as required by law.
Investors: Fletcher Payne, CFO Catalyst Biosciences, Inc. 1.650.871.0761 email@example.com
Media:Josephine Belluardo, Ph.D.LifeSci Public Relations1.646.751.4361 firstname.lastname@example.org